Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2326 to 2340 of 9039 results

  1. Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Male sling for stress urinary incontinence

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Transbronchial lung cryobiopsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Noninvasive Vagus Nerve Stimulation For reactive airway disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. Ocrelizumab for treating relapsing–remitting multiple sclerosis in people 10 to 17 years [TSID12164]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Zavegepant for treating acute migraine [TSID11998]

    Awaiting development Reference number: GID-TA11527 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Migraine trigger site deactivation surgery

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  10. Insertion of a synthetic cartilage for first CMC osteoarthritis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. Naviswiss navigation for total hip replacement

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    Awaiting development Reference number: GID-TA11307 Expected publication date:  06 January 2027

    Technology appraisal guidance
    Awaiting development

  14. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]

    Awaiting development Reference number: GID-TA11969 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Spartan RX point-of-care CYP2C19 test

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation